Oral Wegovy Arrives in the UAE: Novo Nordisk’s First International Market Beyond the U.S.

The first is for long-term weight management in adults with obesity (a BMI of 30 kg/m² or greater) or those who are overweight (a BMI of 27 kg/m² or greater) with at least one weight-related medical condition . The treatment must be used alongside a reduced-calorie diet and increased physical activity .

The second indication is for cardiovascular risk reduction. The pill is approved to reduce the risk of major adverse cardiovascular events (MACE), such as heart attack and stroke, in adults with established cardiovascular disease and either obesity or overweight . This cardiovascular claim distinguishes the Wegovy tablet from some competing oral options .

Clinical Evidence: The OASIS 4 Trial

The regulatory decisions in both the U.S. and UAE rest on results from the Phase 3 OASIS 4 clinical trial. The 64-week study enrolled 307 adults with obesity or overweight with at least one weight-related comorbidity and without diabetes .

When patients adhered to treatment, the 25 mg dose delivered a mean body weight loss of 16.6%, compared to 2.7% for placebo . More than a third of participants (34.4%) lost 20% or more of their body weight . In a broader analysis that included all participants regardless of adherence, the treatment effect was still an average weight loss of approximately 13.6% to 14% . The weight loss achieved with the pill is similar to what the injectable form of Wegovy delivers .

UAE Phased Rollout and the Metabolic Partnership

Novo Nordisk's UAE launch is a multi-step process. The company announced the official availability on June 3, but a phased rollout will follow through an early-access strategic partnership with Metabolic (formerly GluCare.Health), a Dubai-based healthcare provider . Metabolic will be among the first to offer the pill, receiving supply in advance of broader market availability .

To obtain the drug, patients need a prescription following a medical consultation and can join a priority waitlist through Metabolic's digital health platform . Pricing for the UAE market has not been formally announced, though early reports suggest market expectations place it in a similar range to Eli Lilly's competing oral pill, Foundayo, which launched in Dubai in April 2026 .

Crucially, the Dubai logistics infrastructure is positioned to become a nerve centre for Novo Nordisk. Shipments of the pill are already being channeled to as many as 70 countries across the Gulf, Africa, and Central Asia, a strategy enabled by the fact that the tablet requires no cold-chain storage .

U.S. Precedent and Global Ambition

The Wegovy pill was approved by the U.S. FDA on December 22, 2025, as the first oral GLP-1 receptor agonist for chronic weight management . Novo Nordisk launched it in the U.S. in early January 2026 . In its first full quarter (Q1 2026), the drug generated $354 million in U.S. sales and attracted over 1.3 million prescriptions .

The UAE is the first of several international markets Novo Nordisk has planned for the second half of 2026 . The company is backing this expansion with significant manufacturing investments, including a €432 million ($501 million) facility upgrade in Ireland dedicated to producing oral Wegovy . Company executives have described the global push as critical for clawing back ground lost to rival Eli Lilly in the injectable market while also establishing a lead in the emerging oral GLP-1 space .

Competitive Landscape with Eli Lilly

The launch places Novo Nordisk ahead in the international oral obesity pill race. Eli Lilly's oral GLP-1, Foundayo, trails Wegovy in U.S. prescriptions by a ratio of roughly 2-to-1, according to early launch data . However, Lilly is advancing orforglipron, another oral candidate, which is expected to enter the market later in 2026 or 2027, setting the stage for an intensifying tablet war . Both companies are investing heavily to scale manufacturing capacity for oral formulations .

Status of Regulatory Reviews in Other Major Markets

The global rollout is far from complete. Novo Nordisk is actively seeking approval from the European Medicines Agency (EMA). An EU advisory committee has already adopted a positive opinion recommending approval, moving the Wegovy pill closer to becoming the first oral GLP-1 treatment authorized for weight management in Europe . A formal decision is still pending. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) is expected to make a decision by late 2026 .